Form 4: Regeneron EVP Andrew Murphy Reports Stock Gift and Beneficial Ownership
SEC Form 4
Andrew Murphy, EVP of Research at Regeneron Pharmaceuticals, reports a gift of 1,185 common stock shares and updates to his beneficial ownership.
Summary
- On November 8, 2024, Andrew Murphy, the EVP of Research at Regeneron Pharmaceuticals, reported a transaction involving the company's common stock.
- Murphy gifted 1,185 shares of common stock.
- Following the transaction, Murphy directly owns 47,121 shares of Regeneron common stock.
- He also indirectly owns 4,326 shares through a 401(k) plan.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't convey any positive or negative sentiment about the company's performance or prospects.
Industry Context
This filing is a routine disclosure related to executive stock transactions, which are common in publicly traded companies. It provides transparency into the holdings of company insiders.
Key Dates
| Date | Description |
|---|---|
| 11/08/2024 | Date of stock gift transaction and filing date of the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.